Follow us on Twitter
twitter icon@FreshPatents


Factor Viii patents

      

This page is updated frequently with new Factor Viii-related patent applications.




 Adeno-associated virus factor viii vectors patent thumbnailAdeno-associated virus factor viii vectors
The invention provides improved adeno-associated virus (aav) factor viii (fviii) vectors, including aav fviii vectors that produce a functional factor viii polypeptide and aav fviii vectors with high expression activity.. .
Biomarin Pharmaceutical Inc.


 Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same patent thumbnailAdeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same
The invention provides adeno-associated virus (aav) factor viii (fviii)-encoding/expressing vectors and virus, including aav fviii vectors with high expression activity and aav fviii vectors that express full-length or truncated functional fviii protein. The invention also relates to methods of making the herein described aav fviii vectors, recombinant aav fviii virus particles comprising or expressing such vectors, associated pharmaceutical formulations comprising the same and therapeutic uses thereof..
Biomarin Pharmaceutical Inc.


 Factor viii formulations patent thumbnailFactor viii formulations
A factor viii (fviii) composition formulated such that nacl is not present in the final formulation or is present in trace amounts, which allows for a concomitant reduction in the lyophilization cycle time and increased stability of the lyophilized fviii.. .
University Of Connecticut


 Stabilization of factor viii without calcium as an excipient patent thumbnailStabilization of factor viii without calcium as an excipient
The present invention provides a novel albumin-free formulation of recombinant factor viii that does not require calcium ions as an added formulation excipient. The absence of calcium chloride in the formulation results in a number of improvements and benefits for a factor viii formulation.
Advantech Bioscience FarmacÊutica Ltda


 Factor viii chimeric proteins and uses thereof patent thumbnailFactor viii chimeric proteins and uses thereof
The present invention provides a chimeric protein comprising a first polypeptide which comprises a fviii protein and a first ig constant region or a portion thereof and a second polypeptide which comprises a vwf protein comprising the d′ domain and d3 domain of vwf, a xten sequence having less than 288 amino acids in length, and a second ig constant region or a portion thereof, wherein the first polypeptide and the second polypeptide are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins..
Biogen Ma Inc.


 Enhancement of recombinant protein expression with copper patent thumbnailEnhancement of recombinant protein expression with copper
The present invention provides a novel use of copper (cupric ion) for improved cell expression of recombinant proteins, particularly coagulation proteins such as recombinant factor viii, b domain deleted recombinant factor viii, recombinant factor ix and rfvii or rfviia. The use of such cell culture supplement results in higher productivity and robustness of the manufacturing process.
Advantech Bioscience Farmacêutical Ltda


 Factor viii variants having a decreased cellular uptake patent thumbnailFactor viii variants having a decreased cellular uptake
The present invention relates to modified coagulation factors. In particular, the present invention relates to modied factor viii molecules having decreased cellular uptake..
Sanquin Blood Supply Foundation


 Stable factor viii formulations with low sugar-glycine patent thumbnailStable factor viii formulations with low sugar-glycine
The present invention provides a novel albumin-free preparation of factor viii has a high amount of salt and a low concentration of sugar and of glycine. The high salt provides stability and an elegant cake structure as the major crystalline component.
Advantech Bioscience Farmacêutica Ltda


 Factor viii b cell epitope variants having reduced immunogenicity patent thumbnailFactor viii b cell epitope variants having reduced immunogenicity
Provided herein are methods and compositions for preventing or reducing an initial immune response to factor viii in patients suffering from hemophilia a and for reducing the intensity of the immune response in patients having pre-formed inhibitor antibodies against factor viii.. .
Bloodworks


 Factor viii sequences patent thumbnailFactor viii sequences
There is provided a nucleic acid molecule comprising a nucleotide sequence encoding for a functional factor viii protein, wherein the portion of the nucleotide sequence encoding for the b domain of the factor viii protein is between 90 and 111 nucleotides in length and encodes for an amino acid sequence comprising a sequence having at least 85% identity to seq id no: 4 and which comprises six asparagine residues. Also provided is a functional factor viii protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating haemophilia, e.g.
St. Jude Children's Research Hospital


Nucleic acid encoding bispecific antibodies

Various bispecific antibodies that specifically bind to both blood coagulation factor ix/activated blood coagulation factor ix and blood coagulation factor x and functionally substitute for the cofactor function of blood coagulation factor viii, that is, the function to promote activation of blood coagulation factor x by activated blood coagulation factor ix, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor viii were successfully discovered..
Chugai Seiyaku Kabushiki Kaisha

Factor viii molecules with reduced vwf binding

The present invention relates to a recombinant factor viii molecule, wherein said molecule has reduced vwf binding capacity, and wherein said molecule is covalently conjugated with at least one side group.. .
Novo Nordisk A/s

Factor viii fusion protein

The present invention relates to modified coagulation factors. In particular, the present invention relates to conjugated factor viii molecules fused to a polypeptide such as e.g.
Novo Nordisk A/s

Novel albumin-free factor viii formulations

A factor viii composition formulated without albumin, comprising the following formulation excipients in addition to factor viii: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mm to 5 mm calcium salt; 100 mm to 300 mm nacl; and a buffering agent for maintaining a ph of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mm to 5 mm calcium salt; 100 mm to 300 mm nacl; and a buffering agent for maintaining a ph of approximately between 6 and 8.
University Of Connecticut

Factor viii compositions and methods of making and using same

The present invention relates to compositions comprising factor viii coagulation factors linked to extended recombinant polypeptide (xten), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor viii-related diseases, disorders, and conditions.. .
Amunix Operating Inc.

Lipid nanodiscs and nanorods as modulators of clotting factor function in vivo

The present invention includes composition and methods of using a lipid nanodisk or nanotube composition comprising a lipid composition of phosphatidylserine and galactosylceramide and a membrane-bound factor viii protein, a membrane-bound factor ix protein, a membrane-bound factor viii-factor ix protein complex, or a membrane-bound factor v-factor x protein complex in or about the lipid nanodisks or nanotubes.. .
Board Of Regents, The University Of Texas System

Method for improving the stability of purified factor viii after reconstitution

The present disclosure relates to a method for increasing the stability of a factor viii molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the factor viii molecule into a first fragment comprising essentially the a1 domain and the a2 domain and a second fragment comprising essentially the a3 domain, the c1 domain and the c2 domain throughout manufacturing the factor viii molecule. The disclosure further pertains to a method for improving the bioavailability of factor viii after intravenous and non-intravenous injection..
Csl Limited

Recombinant factor viii proteins

Provided are recombinant factor viii proteins, e.g., human factor viii proteins with heterologous moieties inserted into flexible permissive loops located in the factor viii a domains, while retaining the procoagulant activity of factor viii.. .
Biogen Idec Ma Inc.

Process for producing and purifying factor viii and its derivatives

Disclosed is a method for producing proteins having factor viii procoagulant activity in serum-free medium by in vitro culturing of mammalian cells, wherein the serum-free medium contains an inhibitor against the protease released from cultured cells. In accordance with this invention, the inhibitor can protect the cleavage of a target protein during cultivation and increase homogeneity of a target molecule, wherein the inhibitor can be a dextran sulfate.
Sk Chemicals Co., Ltd.

A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag

A process for manufacturing of a factor viii product having a ratio of fviii:c/fviii:ag of at least 0.7 in the factor viii product by using chromatography wherein at least one chromatographic step is performed by means of employing; an affinity chromatography resin having an affinity for specifically binding of factor viii which is effected by an affinity ligand which is immobilised on the affinity chromatography resin, said affinity ligand is a 13 kd yeast derived fab antibody fragment directed to the factor viii molecule. An anionic chromatography resin.
Octapharma Ag

Recombinant factor viii proteins

Provided are recombinant factor viii proteins, e.g., human factor viii proteins, in which one or more amino acids in at least one permissive loops or a3 domain are substituted or deleted, or replaced with heterologous moieties, while retaining the procoagulant activity of factor viii.. .
Biogen Ma Inc.

Methods and assays for factor viii activity

The methods and compositions described herein relate to the measurement of factor viii (fviii) levels and/or activity.. .
The U.s. Government As Represented By The Departme Nt Of Veterans Affairs

Stabilized factor viii variants

The present invention relates to modified coagulation factors. In particular, the present invention relates to stabilized factor viii molecules conjugated with a half life extending moiety as well as use of such molecules..
Novo Nordisk A/s

Targeted delivery of factor viii proteins to platelets

The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with (homology to) human factor viii or biologically active portion(s) thereof, related molecules (such as nucleic acids encoding such polypeptides), compositions (such as pharmaceutical formulations) comprising such polypeptides, and methods of making and using such polypeptides.. .
Novo Nordisk A/s

Cell culture processes

Culturing heterologous protein-secreting mammalian cells, such as cho or bhk cells, at 35.1-36.5° c. And/or at ph 7.15-7.20 and/or at a dissolved co2 concentration of 10% or lower.
Baxalta Gmbh

Optimized human clotting factor viii gene expression cassettes and their use

The invention relates to synthetic liver-specific promoters and expression constructs for producing polypeptides and functional nucleic acids in the liver of a subject. The invention further relates to factor viii proteins containing modifications in the amino acid sequence of the factor viii protein, as well as nucleic acid constructs encoding the factor viii proteins and methods of using these compositions to treat a bleeding disorder..
The University Of North Carolina At Chapel Hill



Factor Viii topics:
  • Factor Viii
  • Nucleotide
  • Antibodies
  • Polynucleotide
  • Polypeptide
  • Sialic Acid
  • Circulatory
  • Recombinant
  • Ethylene Glycol
  • Coagulation
  • Hemophilia
  • Physiologic
  • Endogenous
  • Prophylaxis
  • Blood Coagulation


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Factor Viii for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Factor Viii with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.255

    file did exist - 1224

    1 - 1 - 26